Literature DB >> 2507913

Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox.

N B Gorla1, O S Ledesma, G P Barbieri, I B Larripa.   

Abstract

Chromosomal aberrations were analyzed from cultures of peripheral lymphocytes in 2 groups of chagasic children, before and after treatment with nifurtimox. The mean incidence of chromosomal aberrations increased from control values of 1.75 +/- 1.39 (8 patients) to 23.55 +/- 9.55 (6 patients) at a significance of P less than 0.0001. G-banding analysis of chromosomal aberration sites revealed that treated patients present coincidence in the chromosome regions affected: 1p11, 1q11-12, 9q11-13, 17q11-21, 2p21, 2q23, 2q31, 2q33, 6p21, 6p21, 7q32, 13q14, 13q22, 15q22. These data indicate a non-random distribution of chromosomal aberrations induced by nifurtimox therapeutic treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507913     DOI: 10.1016/0165-1218(89)90165-1

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  9 in total

1.  Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole.

Authors:  S Radhika Prathalingham; Shane R Wilkinson; David Horn; John M Kelly
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

Review 2.  Chagas disease.

Authors:  A R L Teixeira; N Nitz; M C Guimaro; C Gomes; C A Santos-Buch
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

Review 3.  Therapy and prophylaxis of systemic protozoan infections.

Authors:  W C Van Voorhis
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 4.  Emerging and reemerging forms of Trypanosoma cruzi transmission.

Authors:  Maria Aparecida Shikanai Yasuda
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-05-16       Impact factor: 2.747

5.  Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole.

Authors:  Annamaria Buschini; Lisa Ferrarini; Susanna Franzoni; Serena Galati; Mirca Lazzaretti; Francesca Mussi; Cristina Northfleet de Albuquerque; Tânia Maria Araújo Domingues Zucchi; Paola Poli
Journal:  J Parasitol Res       Date:  2009-10-21

Review 6.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.

Authors:  Mario Faúndez; Rodrigo López-Muñoz; Gloria Torres; Antonio Morello; Jorge Ferreira; Ulrike Kemmerling; Myriam Orellana; Juan D Maya
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

8.  Therapy of chagas disease: implications for levels of prevention.

Authors:  Sergio Sosa-Estani; Lisandro Colantonio; Elsa Leonor Segura
Journal:  J Trop Med       Date:  2012-03-05

9.  Differential trypanocidal activity of novel macrolide antibiotics; correlation to genetic lineage.

Authors:  Carolina Aquilino; Maria Luisa Gonzalez Rubio; Elena Maria Seco; Leticia Escudero; Laura Corvo; Manuel Soto; Manuel Fresno; Francisco Malpartida; Pedro Bonay
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.